Abstract |
After the discovery of formoterol and salmeterol, new candidates for long-acting beta2-adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once-daily beta2-adrenoceptor agonists such as arformoterol, carmoterol, indacaterol, GSK-159797, GSK-597901, 159802, 642444 and 678007 are under development for the treatment of asthma and chronic obstructive pulmonary disease. The majority of these compounds are (R,R)-isomers in order to control desensitisation and accumulation. Several options for combination products are currently being evaluated in parallel with the development of these ultra LABAs. Once-daily dosing of an ultra LABA would be a significant convenience and probably a compliance-enhancing advantage leading to improved overall clinical outcomes in patients with asthma and chronic obstructive pulmonary disease. The only limits set for the development of a LABA with a new product profile are medical needs and marketing opportunities.
|
Authors | Mario Cazzola, Maria Gabriella Matera, Jan Lötvall |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 14
Issue 7
Pg. 775-83
(Jul 2005)
ISSN: 1744-7658 [Electronic] England |
PMID | 16022567
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Delayed-Action Preparations
- Drugs, Investigational
- Receptors, Adrenergic, beta-2
|
Topics |
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
(administration & dosage, chemistry, pharmacology)
- Animals
- Asthma
(drug therapy, metabolism)
- Delayed-Action Preparations
(chemistry, pharmacology, therapeutic use)
- Drug Administration Schedule
- Drugs, Investigational
(chemistry, pharmacology, therapeutic use)
- Humans
- Pulmonary Disease, Chronic Obstructive
(drug therapy, metabolism)
- Receptors, Adrenergic, beta-2
(metabolism)
|